# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jackie Robinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML037-SYN
- Date: 2026-07-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Marcus Delacroix-Hale, MD
- Calendar frame: modern shifted

## Reason for visit

Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his son. **S**

## Historical basis

- Jackie Robinson was born on January 31, 1919, in Cairo, Georgia, to a family of sharecroppers. **D**
- On April 15, 1947, he played his first major league game for the Brooklyn Dodgers, ending more than sixty years of segregation in major league baseball. **D**
- His retirement from baseball was announced in January 1957; he then worked in business and as a spokesman and fundraiser for civil rights causes, including the NAACP. **D**
- He was diagnosed with diabetes at about 37, around the time he retired from baseball, and at first kept it private; two of his brothers also had diabetes. **D**
- By 1969, at 50, he had nerve and artery damage in his legs. **D**
- In 1970 he had two mild strokes. **D**
- His eldest son, Jackie Robinson Jr., was killed in an automobile accident on June 17, 1971, at 24. **D**

6 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- He is afraid of losing his sight and his independence. **S**
- He wants to keep working and to stay strong for his family after his son's death. **S**

## Strengths and supports

- Strengths: discipline, a long habit of facing pressure in public, his faith, his work for civil rights, and a household that supports him **S**

## Medications and allergies

- Metformin 1,000 mg oral tablet, one tablet twice daily with meals **S**
- Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 **S**
- Lisinopril 20 mg oral tablet, one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) **S**
- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- about 1957: Diabetes diagnosed at about 37, around his retirement from baseball **D** (CLM-0005)
- by 1969: Nerve and artery damage in both legs **D** (CLM-0006)
- 1970: Two mild strokes **D** (CLM-0007)

## Procedures and immunizations

- 2026-07-27 to 2026-07-27: Twelve-lead electrocardiogram **S**
- 2026-07-27 to 2026-07-27: Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses **S**


## Family history

- brother: Two of his brothers had diabetes **D** (CLM-0005)
- natural son: His eldest son died in an automobile accident at 24 **D** (CLM-0011)

## Measurements

Hemoglobin A1c: 10.4% (high); Glucose (random): 248 mg/dL (high); Sodium: 137 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.12 mg/dL; eGFR (CKD-EPI 2021, race-free): 79 mL/min/1.73 m² (low); Urine albumin-to-creatinine ratio: 86 mg/g (high); Total cholesterol: 226 mg/dL (high); LDL cholesterol: 142 mg/dL (high); HDL cholesterol: 38 mg/dL (low); Triglycerides: 230 mg/dL (high); ALT: 28 U/L; AST: 24 U/L; Hemoglobin: 13.9 g/dL; Platelets: 250 10*3/uL; Vitamin B12: 380 pg/mL; TSH: 1.8 mIU/L; PHQ-9: 9. All results are synthetic.

BP 152/92 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 104 kg; BMI 32.1 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, direct and composed; grief evident when speaking of his son; no thoughts of self-harm; PHQ-9 score 9. Functional status: Independent in daily activities; cannot read print or drive safely with his present vision; walks about one block before calf pain stops him. Physical examination is intentionally limited. **S**

## Assessment

1. Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arranged; status draft. **S**
2. Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arranged; status draft. **S**
3. Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%); status draft. **S**
4. Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg); status draft. **S**
5. Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79; status draft. **S**
6. Chronic kidney disease G2 A2; status draft. **S**
7. Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulses; status draft. **S**
8. Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testing; status draft. **S**
9. History of two mild strokes a year ago, without lasting weakness; status draft. **S**
10. Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dL; status draft. **S**
11. Bereavement: his eldest son died in a car crash six weeks ago; status draft. **S**

## Plan

- Urgent retina consultation within 48 hours for blurred vision with new floaters in a man with long-standing diabetes: dilated examination, OCT, and treatment of any proliferative retinopathy or macular edema; same-day attendance for a curtain over the vision or flashes. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); Diabetic Retinopathy Preferred Practice Pattern (2025) **S**
- Glucose: continue metformin and basal insulin, titrated slowly by a written plan so that the A1c falls gradually; rescue glucagon; diabetes self-management education adapted for low vision (a talking glucose meter, an insulin pen with audible dose clicks, large-print plans). Guideline: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026); 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**
- Cardiovascular risk: atorvastatin increased to 80 mg, aspirin continued, baseline ECG; cardiology evaluation of exertional chest tightness with a pharmacologic stress test, since calf pain limits walking. Guideline: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026) **S**
- Legs and feet: comprehensive foot examination today; ankle-brachial index; daily foot checks with a magnifying mirror and a bright lamp, protective shoes; podiatry. Guideline: 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024) **S**
- Kidneys: repeat urine albumin and kidney function after any change in kidney medicines; no NSAIDs. Guideline: 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Grief and mood: acknowledge the loss, PHQ-9 now and at three months, and an offer of the health center's grief counselor, which he accepted; call or text 988 if thoughts of self-harm ever arise. Guideline: 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 (2026); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026); Depression and Suicide Risk in Adults: Screening (2023) **S**

## Guideline basis

- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes-2026 (2026), American Diabetes Association (Diabetes Care 2026;49(Suppl 1))
- Diabetic Retinopathy Preferred Practice Pattern (2025), American Academy of Ophthalmology (Ophthalmology 2025; Lim JI, et al.)
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024), American College of Cardiology and American Heart Association (Circulation 2024)
- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023)
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021), American Heart Association and American Stroke Association (Stroke 2021)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension, hyperlipidemia, ischemic heart disease, chronic kidney disease and depression monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force
